NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $72.00 -1.16 (-1.59%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$72.09 +0.09 (+0.13%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ANI Pharmaceuticals Stock (NASDAQ:ANIP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$71.90▼$73.5450-Day Range$70.16▼$78.8552-Week Range$69.58▼$95.57Volume286,882 shsAverage Volume329,550 shsMarket Capitalization$1.65 billionP/E Ratio15.52Dividend YieldN/APrice Target$99.60Consensus RatingHold Company Overview ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders. ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases. Its products include Cortrophin-Zinc, a repository corticotropin injection used for certain inflammatory and autoimmune conditions, along with a range of other prescription therapies. The company also maintains a pipeline of internally developed, acquired and partnered products. ANI Pharmaceuticals primarily serves the United States through its commercial, manufacturing and distribution operations. The company’s corporate headquarters are in Princeton, New Jersey, and it operates pharmaceutical manufacturing and development facilities in the United States. Nikhil Lalwani serves as president and chief executive officer.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreANIP MarketRank™: 3.856324084925 of 5 starsANI Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 123rd out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingANI Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialANI Pharmaceuticals has a consensus price target of $99.60, representing about 38.3% upside from its current price of $72.00.Amount of Analyst CoverageANI Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.22% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 7.22% in the coming year, from $7.76 to $8.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 15.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.63.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 15.52, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.85.Price to Earnings Growth RatioANI Pharmaceuticals has a PEG Ratio of 2.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.45% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 0.55%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentANI Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows5 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,220,970.00 in company stock.Percentage Held by Insiders8.10% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesInsider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $207,679.50 in Stock2 hours ago | insidertrades.comJ.P. Morgan Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP)October 24, 2026 | theglobeandmail.comThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Starlink dish and AI satellite Elon launches. When Nvidia tried to buy the company, Elon reportedly fought the deal. Now his filing for 1,000,000 satellites could expand its revenue stream sharply. Dylan believes the stock could see significant movement starting December 8th.October 31 at 1:00 AM | Behind the Markets (Ad)ANI Pharmaceuticals (NASDAQ:ANIP) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?October 24, 2026 | americanbankingnews.comANI Pharmaceuticals' Eye-Care Franchise Faces New Competition, Oppenheimer SaysOctober 23, 2026 | finance.yahoo.comANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in StockOctober 17, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of StockOctober 14, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares of StockOctober 1, 2026 | insidertrades.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $78.94 at the beginning of 2026. Since then, ANIP stock has decreased by 8.8% and is now trading at $72.00. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Friday, August, 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The company's quarterly revenue was up 25.8% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional shareholders include Bridge City Capital LLC (0.23%), Profund Advisors LLC (0.10%), Artemis Investment Management LLP (0.09%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.08%). Insiders that own company stock include Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Thomas Haughey, Patrick D Walsh, Thomas Andrew Rowland, Jeanne Thoma, Renee P Tannenbaum, Antonio R Pera and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings8/07/2026Today10/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANIP's financial health is in the Red zone, according to TradeSmith. ANIP has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees970Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$99.60 High Price Target$119.00 Low Price Target$85.00 Potential Upside/Downside+38.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$4.64 Trailing P/E Ratio15.52 Forward P/E Ratio9.28 P/E Growth2.36Net Income$78.34 million Net Margins11.07% Pretax Margin14.57% Return on Equity27.37% Return on Assets10.47% Debt Debt-to-Equity Ratio0.99 Current Ratio2.91 Quick Ratio2.41 Sales & Book Value Annual Sales$883.37 million Price / Sales1.87 Cash Flow$9.78 per share Price / Cash Flow7.36 Book Value$24.03 per share Price / Book3.00Miscellaneous Outstanding Shares22,970,000Free Float21,109,000Market Cap$1.65 billion OptionableOptionable Beta0.50 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ANIP) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
